In his weekly "My Take" blog on the US Food and Drug Administration's web site, Andrew von Eschenbach, who will soon be relinquishing his post as Commissioner in the incoming Barack Obama administration, gave his annual self-appraisal of what had been achieved during the past year, which he says is a useful exercise for government entities such as the FDA.
He said: "when I arrived at FDA more than three years ago, I set five priorities or resolutions. They were to prepare the agency for strong performance in the case of a public health emergency; improve the FDA's internal and external communications; maximize the use of electronic data and insights provided by projects in personalized medicine, like the Human Genome Project; continue the implementation of modern scientific tools for regulation in medical products through our agencies our agency's Critical Path Initiative; and advance the FDA's outreach globally to ensure that imported food and drugs measure up to the United States' standards."
In his January 2 message, he claims that "the progress that we've made toward all of these goals now serves as a New Year's resolution to do even more."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze